BioXcel Therapeutics (BTAI) CEO Vimal Mehta exercises RSUs for 383 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BioXcel Therapeutics, Inc. CEO and President Vimal Mehta exercised restricted stock units into common shares in routine compensation-related transactions. On March 14 and March 15, 2026, he exercised a total of 383 RSUs at $0.00 per unit, receiving 383 shares of common stock.

After these exercises, Mehta directly owns 21,259 shares of common stock and holds remaining RSUs of 1,532 and 488 units from prior grants. The filing also shows indirect common stock holdings of 125 shares held by his spouse and 480,343 shares held of record by BioXcel LLC, a subsidiary of BioXcel Holdings, Inc., with detailed beneficial ownership and pecuniary interest disclaimers.

Insider Trade Summary

383 shares exercised/converted

Mixed 6 txns

Insider Mehta Vimal

Role CEO and President

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	219	$0.00	--
Exercise	Common Stock	219	$0.00	--
Exercise	Restricted Stock Units	164	$0.00	--
Exercise	Common Stock	164	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 1,532 shares (Direct); Common Stock — 21,259 shares (Direct); Common Stock — 125 shares (Indirect, By Spouse)

Footnotes (1)

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

Form 4 Insider Transactions: What Each Field Means →

03/16/2026 - 08:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mehta Vimal

(Last)

(First)

(Middle)

C/O BIOXCEL THERAPEUTICS, INC.

555 LONG WHARF DRIVE, 12TH FLOOR

(Street)

NEW HAVEN

06511

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BioXcel Therapeutics, Inc. [ BTAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/14/2026		M		164	A	⁽¹⁾	21,040	D
Common Stock	03/15/2026		M		219	A	⁽¹⁾	21,259	D
Common Stock								125	I	By Spouse
Common Stock								480,343	I	By BioXcel LLC⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	03/14/2026		M			164	⁽³⁾	⁽³⁾	Common Stock	164	$0	488	D
Restricted Stock Units	⁽¹⁾	03/15/2026		M			219	⁽⁴⁾	⁽⁴⁾	Common Stock	219	$0	1,532	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

3. On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

4. On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

	/s/ Richard Steinhart, Attorney-in-Fact for Vimal Mehta, Ph.D.	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did BTAI CEO Vimal Mehta report on this Form 4?

Vimal Mehta reported exercising restricted stock units into common stock. On March 14 and March 15, 2026, he converted 383 RSUs at $0.00 per unit into 383 shares of BioXcel Therapeutics common stock, with no open-market purchases or sales disclosed.

How many BioXcel Therapeutics (BTAI) shares does Vimal Mehta hold directly after these transactions?

Following the reported RSU exercises, Vimal Mehta directly holds 21,259 shares of BioXcel Therapeutics common stock. This total reflects the addition of 383 shares received upon RSU conversion at $0.00 per share, as shown in the non-derivative transaction entries for common stock.

Were any BioXcel Therapeutics (BTAI) shares sold in Vimal Mehta’s latest Form 4 filing?

No shares were sold in this filing. All coded transactions are “M”, indicating exercises or conversions of derivative securities, specifically restricted stock units, into common stock. The transaction summary shows no open-market buys or sells and a net buy/sell direction marked as neutral.

What restricted stock unit (RSU) grants underpin Vimal Mehta’s BTAI Form 4 transactions?

The RSU activity relates to grants originally awarded on March 14, 2022 for 2,609 RSUs and March 15, 2023 for 3,500 RSUs. Each grant vests 25% on the first anniversary, then 6.25% quarterly thereafter, subject to his continuous employment with BioXcel Therapeutics.

What indirect BioXcel Therapeutics (BTAI) holdings are associated with Vimal Mehta?

The filing lists 125 common shares held indirectly by his spouse and 480,343 common shares held of record by BioXcel LLC. Footnotes explain BioXcel LLC is a subsidiary of BioXcel Holdings, Inc., and describe Mehta’s roles and his disclaimer of beneficial ownership except for his pecuniary interest.

How many restricted stock units remain for Vimal Mehta after the reported BTAI RSU exercises?

After the reported conversions, Mehta retains 1,532 RSUs from the March 15, 2023 grant and 488 RSUs from the March 14, 2022 grant. Each RSU represents a contingent right to receive one share of BioXcel Therapeutics common stock, subject to the specified vesting schedules and continued employment conditions.